{"transactions":[{"id":757979,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2026-06-01T21:20:06.000Z","date":"2026-06-01","kind":"sale","planned":false,"acquired":false,"shares":476,"price":21.14,"value":10062.64,"ownership":{"direct":true},"balance_after":130142,"source":{"system":"sec-edgar","filing":"0000897069-26-001297","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706926001297/form4.xml","form_type":"4"}},{"id":757978,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2026-06-01T21:20:06.000Z","date":"2026-06-01","kind":"sale","planned":false,"acquired":false,"shares":24524,"price":20,"value":490480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":130618,"source":{"system":"sec-edgar","filing":"0000897069-26-001297","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706926001297/form4.xml","form_type":"4"}},{"id":975208,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T21:52:32.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":false,"shares":395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.4,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":395},"source":{"system":"sec-edgar","filing":"0000897069-25-001793","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001793/form4.xml","form_type":"4"}},{"id":975207,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-10T21:52:32.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":446,"price":7.92,"value":3532.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.91 to $7.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":155142,"source":{"system":"sec-edgar","filing":"0000897069-25-001793","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001793/form4.xml","form_type":"4"}},{"id":975206,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-10T21:52:32.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":395,"price":8.04,"value":3175.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":155588,"source":{"system":"sec-edgar","filing":"0000897069-25-001793","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001793/form4.xml","form_type":"4"}},{"id":975205,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-10T21:52:32.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":true,"shares":395,"price":6.4,"value":2528.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":155983,"source":{"system":"sec-edgar","filing":"0000897069-25-001793","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001793/form4.xml","form_type":"4"}},{"id":975204,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-10T21:52:32.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":2666,"price":7.95,"value":21194.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.80 to $8.33. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":155588,"source":{"system":"sec-edgar","filing":"0000897069-25-001793","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001793/form4.xml","form_type":"4"}},{"id":975203,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-10T21:52:32.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":3105,"price":8.59,"value":26671.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.50 to $9.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":158254,"source":{"system":"sec-edgar","filing":"0000897069-25-001793","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001793/form4.xml","form_type":"4"}},{"id":978318,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-08T21:36:39.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":42,"price":13.16,"value":552.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $13.00 to $13.26. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":161359,"source":{"system":"sec-edgar","filing":"0000897069-25-001774","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001774/form4.xml","form_type":"4"}},{"id":978317,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-08T21:36:39.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":1745,"price":12.29,"value":21446.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $12.02 to $12.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":161401,"source":{"system":"sec-edgar","filing":"0000897069-25-001774","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001774/form4.xml","form_type":"4"}},{"id":978316,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-08T21:36:39.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":14508,"price":11.4,"value":165391.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $11.00 to $12.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":163146,"source":{"system":"sec-edgar","filing":"0000897069-25-001774","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001774/form4.xml","form_type":"4"}},{"id":978315,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2025-12-08T21:36:39.000Z","date":"2025-12-04","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":9.06,"value":45300.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.00 to $9.54. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":177654,"source":{"system":"sec-edgar","filing":"0000897069-25-001774","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706925001774/form4.xml","form_type":"4"}},{"id":1136244,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:30:15.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These options are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the options, and shares exercisable thereunder, held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such options."}],"balance_after":19000,"derivative":{"exercise_price":0.3202,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-25-014483","document":"form4-05232025_040509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000141588925014483/form4-05232025_040509.xml","form_type":"4"}},{"id":1481434,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T21:10:20.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder\nmeeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These options are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the options, and shares exercisable thereunder, held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such options."}],"balance_after":19000,"derivative":{"exercise_price":0.709,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-24-016698","document":"form4-06132024_090616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000141588924016698/form4-06132024_090616.xml","form_type":"4"}},{"id":1818532,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-02T21:06:37.000Z","date":"2023-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1587302,"price":1.26,"value":2000000.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and Cambrian BioPharma Inc.  This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":3653120,"source":{"system":"sec-edgar","filing":"0000897069-23-001052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706923001052/form4.xml","form_type":"4"}},{"id":1831206,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-12T20:29:20.000Z","date":"2023-07-10","kind":"grant","planned":false,"acquired":true,"shares":14550,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":14550,"derivative":{"exercise_price":1.22,"expiration_date":"2033-07-09","underlying":"Common Stock","underlying_shares":14550},"source":{"system":"sec-edgar","filing":"0001209191-23-042079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919123042079/doc4.xml","form_type":"4"}},{"id":1831205,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-12T20:29:20.000Z","date":"2023-07-10","kind":"grant","planned":false,"acquired":true,"shares":4466,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5240422,"source":{"system":"sec-edgar","filing":"0001209191-23-042079","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919123042079/doc4.xml","form_type":"4"}},{"id":2199624,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-01T21:45:15.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":14550,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":14550,"derivative":{"exercise_price":2.05,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":14550},"source":{"system":"sec-edgar","filing":"0001567619-22-014723","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922014723/doc1.xml","form_type":"4/A","original_submission_date":"2022-06-14"}},{"id":2199623,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Unit Grant","published_at":"2022-08-01T21:45:15.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":4466,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Amendment filed solely to correct the number of shares owned."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5235956,"source":{"system":"sec-edgar","filing":"0001567619-22-014723","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922014723/doc1.xml","form_type":"4/A","original_submission_date":"2022-06-14"}},{"id":2233368,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-14T20:54:29.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":14550,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":14550,"derivative":{"exercise_price":2.05,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":14550},"source":{"system":"sec-edgar","filing":"0001567619-22-012841","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922012841/doc1.xml","form_type":"4"}},{"id":2233367,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Unit Grant","published_at":"2022-06-14T20:54:29.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":4466,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5235954,"source":{"system":"sec-edgar","filing":"0001567619-22-012841","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922012841/doc1.xml","form_type":"4"}},{"id":2236861,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T18:18:16.000Z","date":"2022-03-02","kind":"purchase","acquired":true,"shares":1203,"price":3.2,"value":3849.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed solely to correct the number of shares beneficially owned following the transaction reported herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5231488,"source":{"system":"sec-edgar","filing":"0001567619-22-012647","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922012647/doc1.xml","form_type":"4/A","original_submission_date":"2022-03-02"}},{"id":2293130,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:25:07.000Z","date":"2021-03-23","kind":"purchase","acquired":true,"shares":9500,"price":14.34,"value":136230.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on March 24, 2021, overstated the number of shares purchased."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4798293,"source":{"system":"sec-edgar","filing":"0001567619-22-008804","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922008804/doc1.xml","form_type":"4/A","original_submission_date":"2021-03-24"}},{"id":2293128,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-21T20:22:23.000Z","date":"2021-02-18","kind":"purchase","acquired":true,"shares":752,"price":19.75,"value":14852.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on February 19, 2021, overstated the number of shares purchased."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on February 19, 2021, overstated the number of shares purchased."}],"balance_after":4690905,"source":{"system":"sec-edgar","filing":"0001567619-22-008802","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922008802/doc1.xml","form_type":"4/A","original_submission_date":"2021-02-19"}},{"id":2362975,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-02T18:40:28.000Z","date":"2022-03-02","kind":"purchase","acquired":true,"shares":1203,"price":3.2,"value":3849.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5231989,"source":{"system":"sec-edgar","filing":"0001567619-22-006006","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922006006/doc1.xml","form_type":"4"}},{"id":2367158,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-01T23:55:44.000Z","date":"2022-03-01","kind":"purchase","acquired":true,"shares":2458,"price":3.6,"value":8848.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5230786,"source":{"system":"sec-edgar","filing":"0001567619-22-005915","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922005915/doc1.xml","form_type":"4"}},{"id":2367157,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-01T23:55:44.000Z","date":"2022-02-28","kind":"purchase","acquired":true,"shares":42,"price":3.6,"value":151.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5228328,"source":{"system":"sec-edgar","filing":"0001567619-22-005915","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922005915/doc1.xml","form_type":"4"}},{"id":2370291,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-28T21:53:24.000Z","date":"2022-02-25","kind":"purchase","acquired":true,"shares":2500,"price":3.65,"value":9125.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5228286,"source":{"system":"sec-edgar","filing":"0001567619-22-005792","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922005792/doc1.xml","form_type":"4"}},{"id":2376309,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T00:12:12.000Z","date":"2022-02-24","kind":"purchase","acquired":true,"shares":15000,"price":3.63,"value":54450.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5225786,"source":{"system":"sec-edgar","filing":"0001567619-22-005517","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922005517/doc1.xml","form_type":"4"}},{"id":2376308,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T00:12:12.000Z","date":"2022-02-23","kind":"purchase","acquired":true,"shares":2500,"price":3.8,"value":9500.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5210786,"source":{"system":"sec-edgar","filing":"0001567619-22-005517","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922005517/doc1.xml","form_type":"4"}},{"id":2383702,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T16:36:16.000Z","date":"2022-02-18","kind":"purchase","acquired":true,"shares":15000,"price":3.97,"value":59550.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5208286,"source":{"system":"sec-edgar","filing":"0001567619-22-005191","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922005191/doc1.xml","form_type":"4"}},{"id":2383701,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T16:36:16.000Z","date":"2022-02-17","kind":"purchase","acquired":true,"shares":4949,"price":4.17,"value":20637.33,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5193286,"source":{"system":"sec-edgar","filing":"0001567619-22-005191","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922005191/doc1.xml","form_type":"4"}},{"id":2393195,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-16T23:54:00.000Z","date":"2022-02-16","kind":"purchase","acquired":true,"shares":2551,"price":4.25,"value":10841.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5188337,"source":{"system":"sec-edgar","filing":"0001567619-22-004777","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922004777/doc1.xml","form_type":"4"}},{"id":2393194,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-16T23:54:00.000Z","date":"2022-02-14","kind":"purchase","acquired":true,"shares":10000,"price":4.18,"value":41800.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5185786,"source":{"system":"sec-edgar","filing":"0001567619-22-004777","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922004777/doc1.xml","form_type":"4"}},{"id":2399621,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T00:19:52.000Z","date":"2022-02-11","kind":"purchase","acquired":true,"shares":12500,"price":4.4,"value":55000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5175786,"source":{"system":"sec-edgar","filing":"0001567619-22-004545","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922004545/doc1.xml","form_type":"4"}},{"id":2399620,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T00:19:52.000Z","date":"2022-02-10","kind":"purchase","acquired":true,"shares":5000,"price":4.58,"value":22900.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.55 to $4.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5163286,"source":{"system":"sec-edgar","filing":"0001567619-22-004545","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922004545/doc1.xml","form_type":"4"}},{"id":2409186,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-08T23:40:24.000Z","date":"2022-02-08","kind":"purchase","acquired":true,"shares":10000,"price":4.33,"value":43300.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5158286,"source":{"system":"sec-edgar","filing":"0001567619-22-002935","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922002935/doc1.xml","form_type":"4"}},{"id":2409185,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-08T23:40:24.000Z","date":"2022-02-04","kind":"purchase","acquired":true,"shares":2500,"price":4.45,"value":11125.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5148286,"source":{"system":"sec-edgar","filing":"0001567619-22-002935","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922002935/doc1.xml","form_type":"4"}},{"id":2409184,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-08T23:40:24.000Z","date":"2022-02-03","kind":"purchase","acquired":true,"shares":17500,"price":4.65,"value":81375.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5145786,"source":{"system":"sec-edgar","filing":"0001567619-22-002935","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922002935/doc1.xml","form_type":"4"}},{"id":2421694,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T16:26:15.000Z","date":"2022-01-28","kind":"purchase","acquired":true,"shares":8900,"price":4.22,"value":37558.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5128286,"source":{"system":"sec-edgar","filing":"0001567619-22-002034","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922002034/doc1.xml","form_type":"4"}},{"id":2421693,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T16:26:15.000Z","date":"2022-01-27","kind":"purchase","acquired":true,"shares":6100,"price":4.31,"value":26291.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5119386,"source":{"system":"sec-edgar","filing":"0001567619-22-002034","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922002034/doc1.xml","form_type":"4"}},{"id":2424509,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-27T15:31:03.000Z","date":"2022-01-26","kind":"purchase","acquired":true,"shares":29900,"price":4.62,"value":138138.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5113286,"source":{"system":"sec-edgar","filing":"0001567619-22-001804","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001804/doc1.xml","form_type":"4"}},{"id":2424508,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-27T15:31:03.000Z","date":"2022-01-25","kind":"purchase","acquired":true,"shares":20100,"price":4.86,"value":97686.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5083386,"source":{"system":"sec-edgar","filing":"0001567619-22-001804","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001804/doc1.xml","form_type":"4"}},{"id":2427144,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-25T14:14:59.000Z","date":"2022-01-24","kind":"purchase","acquired":true,"shares":22707,"price":4.69,"value":106495.83,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5063286,"source":{"system":"sec-edgar","filing":"0001567619-22-001634","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001634/doc1.xml","form_type":"4"}},{"id":2427143,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-25T14:14:59.000Z","date":"2022-01-21","kind":"purchase","acquired":true,"shares":24703,"price":4.94,"value":122032.82,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5040579,"source":{"system":"sec-edgar","filing":"0001567619-22-001634","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001634/doc1.xml","form_type":"4"}},{"id":2429317,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-21T23:20:00.000Z","date":"2022-01-20","kind":"purchase","acquired":true,"shares":20000,"price":5.17,"value":103400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":5015876,"source":{"system":"sec-edgar","filing":"0001567619-22-001464","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001464/doc1.xml","form_type":"4"}},{"id":2429316,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-21T23:20:00.000Z","date":"2022-01-19","kind":"purchase","acquired":true,"shares":10244,"price":4.97,"value":50912.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4995876,"source":{"system":"sec-edgar","filing":"0001567619-22-001464","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001464/doc1.xml","form_type":"4"}},{"id":2431513,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T14:07:17.000Z","date":"2022-01-18","kind":"purchase","acquired":true,"shares":10000,"price":5.08,"value":50800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4985632,"source":{"system":"sec-edgar","filing":"0001567619-22-001342","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001342/doc1.xml","form_type":"4"}},{"id":2434240,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-18T15:20:16.000Z","date":"2022-01-14","kind":"purchase","acquired":true,"shares":6219,"price":4.99,"value":31032.81,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.95 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4975632,"source":{"system":"sec-edgar","filing":"0001567619-22-001230","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001230/doc1.xml","form_type":"4"}},{"id":2434239,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-18T15:20:16.000Z","date":"2022-01-13","kind":"purchase","acquired":true,"shares":19953,"price":5.13,"value":102358.89,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4969413,"source":{"system":"sec-edgar","filing":"0001567619-22-001230","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001230/doc1.xml","form_type":"4"}},{"id":2436280,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T21:14:46.000Z","date":"2022-01-12","kind":"purchase","acquired":true,"shares":9202,"price":5.22,"value":48034.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.20 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4949460,"source":{"system":"sec-edgar","filing":"0001567619-22-001167","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001167/doc1.xml","form_type":"4"}},{"id":2436279,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T21:14:46.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":10845,"price":5.18,"value":56177.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4940258,"source":{"system":"sec-edgar","filing":"0001567619-22-001167","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001167/doc1.xml","form_type":"4"}},{"id":2438300,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:29:46.000Z","date":"2022-01-10","kind":"purchase","acquired":true,"shares":10000,"price":5.28,"value":52800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4929413,"source":{"system":"sec-edgar","filing":"0001567619-22-001007","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922001007/doc1.xml","form_type":"4"}},{"id":2455274,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-03T14:40:00.000Z","date":"2021-12-30","kind":"purchase","acquired":true,"shares":1127,"price":4.85,"value":5465.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4919413,"source":{"system":"sec-edgar","filing":"0001567619-22-000008","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761922000008/doc1.xml","form_type":"4"}},{"id":2456547,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-30T17:25:40.000Z","date":"2021-12-29","kind":"purchase","acquired":true,"shares":69000,"price":4.98,"value":343620.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4918286,"source":{"system":"sec-edgar","filing":"0001567619-21-022649","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921022649/doc1.xml","form_type":"4"}},{"id":2457474,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-29T17:04:09.000Z","date":"2021-12-28","kind":"purchase","acquired":true,"shares":11288,"price":5.28,"value":59600.64,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4849286,"source":{"system":"sec-edgar","filing":"0001567619-21-022593","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921022593/doc1.xml","form_type":"4"}},{"id":2458982,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-27T23:08:04.000Z","date":"2021-12-27","kind":"purchase","acquired":true,"shares":3712,"price":5.3,"value":19673.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4837998,"source":{"system":"sec-edgar","filing":"0001567619-21-022540","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921022540/doc1.xml","form_type":"4"}},{"id":2460235,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T23:55:39.000Z","date":"2021-12-23","kind":"purchase","acquired":true,"shares":11000,"price":5.27,"value":57970.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.20 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4834286,"source":{"system":"sec-edgar","filing":"0001567619-21-022520","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921022520/doc1.xml","form_type":"4"}},{"id":2463222,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T20:54:27.000Z","date":"2021-12-17","kind":"purchase","acquired":true,"shares":117,"price":5.29,"value":618.93,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4823286,"source":{"system":"sec-edgar","filing":"0001567619-21-022392","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921022392/doc1.xml","form_type":"4"}},{"id":2464542,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-20T22:18:12.000Z","date":"2021-12-16","kind":"purchase","acquired":true,"shares":10925,"price":5.25,"value":57356.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.23 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4823169,"source":{"system":"sec-edgar","filing":"0001567619-21-022339","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921022339/doc1.xml","form_type":"4"}},{"id":2725687,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:34:30.000Z","date":"2021-05-05","kind":"purchase","acquired":true,"shares":350,"price":12,"value":4200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4812244,"source":{"system":"sec-edgar","filing":"0001567619-21-009211","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921009211/doc1.xml","form_type":"4"}},{"id":2743606,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-21T19:50:32.000Z","date":"2021-04-20","kind":"purchase","acquired":true,"shares":385,"price":12.77,"value":4916.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.75 to $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4811894,"source":{"system":"sec-edgar","filing":"0001567619-21-008410","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921008410/doc1.xml","form_type":"4"}},{"id":2744384,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T19:37:06.000Z","date":"2021-04-19","kind":"purchase","acquired":true,"shares":1965,"price":13.38,"value":26291.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4811509,"source":{"system":"sec-edgar","filing":"0001567619-21-008359","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921008359/doc1.xml","form_type":"4"}},{"id":2749894,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-14T20:41:42.000Z","date":"2021-04-13","kind":"purchase","acquired":true,"shares":2000,"price":14,"value":28000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4809544,"source":{"system":"sec-edgar","filing":"0001567619-21-008047","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921008047/doc1.xml","form_type":"4"}},{"id":2753489,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-08T22:13:34.000Z","date":"2021-04-07","kind":"purchase","acquired":true,"shares":2000,"price":14,"value":28000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4807544,"source":{"system":"sec-edgar","filing":"0001567619-21-007835","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921007835/doc1.xml","form_type":"4"}},{"id":2762698,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:56:27.000Z","date":"2021-04-01","kind":"purchase","acquired":true,"shares":1000,"price":14,"value":14000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4805544,"source":{"system":"sec-edgar","filing":"0001567619-21-007469","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921007469/doc1.xml","form_type":"4"}},{"id":2767275,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-31T19:41:40.000Z","date":"2021-03-30","kind":"purchase","acquired":true,"shares":2000,"price":12,"value":24000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.99 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4804544,"source":{"system":"sec-edgar","filing":"0001567619-21-007281","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921007281/doc1.xml","form_type":"4"}},{"id":2772481,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T16:40:43.000Z","date":"2021-03-24","kind":"purchase","acquired":true,"shares":3750,"price":14.12,"value":52950.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4802544,"source":{"system":"sec-edgar","filing":"0001567619-21-006934","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921006934/doc1.xml","form_type":"4"}},{"id":2773819,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-24T20:21:36.000Z","date":"2021-03-23","kind":"purchase","acquired":true,"shares":10000,"price":14.34,"value":143400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4798794,"source":{"system":"sec-edgar","filing":"0001567619-21-006867","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921006867/doc1.xml","form_type":"4"}},{"id":2775559,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-23T16:32:34.000Z","date":"2021-03-22","kind":"purchase","acquired":true,"shares":2183,"price":15.02,"value":32788.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4788794,"source":{"system":"sec-edgar","filing":"0001567619-21-006778","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921006778/doc1.xml","form_type":"4"}},{"id":2778235,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-19T19:44:02.000Z","date":"2021-03-18","kind":"purchase","acquired":true,"shares":817,"price":15.25,"value":12459.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4786611,"source":{"system":"sec-edgar","filing":"0001567619-21-006681","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921006681/doc1.xml","form_type":"4"}},{"id":2798118,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-10T22:37:16.000Z","date":"2021-03-08","kind":"purchase","acquired":true,"shares":1000,"price":15.249,"value":15249.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.20 to $15.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4785794,"source":{"system":"sec-edgar","filing":"0001567619-21-006035","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921006035/doc1.xml","form_type":"4"}},{"id":2804298,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-08T21:48:07.000Z","date":"2021-03-05","kind":"purchase","acquired":true,"shares":8000,"price":13.75,"value":110000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.50 to $14.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4784794,"source":{"system":"sec-edgar","filing":"0001567619-21-005823","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921005823/doc1.xml","form_type":"4"}},{"id":2807432,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-05T18:55:55.000Z","date":"2021-03-04","kind":"purchase","acquired":true,"shares":2000,"price":14.125,"value":28250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4776794,"source":{"system":"sec-edgar","filing":"0001567619-21-005716","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921005716/doc1.xml","form_type":"4"}},{"id":2807431,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-05T18:55:55.000Z","date":"2021-03-03","kind":"purchase","acquired":true,"shares":3000,"price":15.85,"value":47550.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.75 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4774794,"source":{"system":"sec-edgar","filing":"0001567619-21-005716","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921005716/doc1.xml","form_type":"4"}},{"id":2816740,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-03T22:22:31.000Z","date":"2021-03-02","kind":"purchase","acquired":true,"shares":3000,"price":16.25,"value":48750.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.00 to $16.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian BioPharma Inc, a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4771794,"source":{"system":"sec-edgar","filing":"0001567619-21-005574","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000156761921005574/doc1.xml","form_type":"4"}},{"id":2823238,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-02T21:15:31.000Z","date":"2021-02-26","kind":"purchase","acquired":true,"shares":5000,"price":16.25,"value":81250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.75 to $16.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4768794,"source":{"system":"sec-edgar","filing":"0001209191-21-015883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121015883/doc4.xml","form_type":"4"}},{"id":2831051,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-26T21:05:51.000Z","date":"2021-02-25","kind":"purchase","acquired":true,"shares":12000,"price":15.79,"value":189480.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.59 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4763794,"source":{"system":"sec-edgar","filing":"0001209191-21-014686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121014686/doc4.xml","form_type":"4"}},{"id":2831050,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-26T21:05:51.000Z","date":"2021-02-24","kind":"purchase","acquired":true,"shares":900,"price":18.42,"value":16578.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.95 to $18.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4751794,"source":{"system":"sec-edgar","filing":"0001209191-21-014686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121014686/doc4.xml","form_type":"4"}},{"id":2831049,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-26T21:05:51.000Z","date":"2021-02-24","kind":"purchase","acquired":true,"shares":18100,"price":16.84,"value":304804.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.43 to $17.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4750894,"source":{"system":"sec-edgar","filing":"0001209191-21-014686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121014686/doc4.xml","form_type":"4"}},{"id":2834066,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-25T22:55:26.000Z","date":"2021-02-23","kind":"purchase","acquired":true,"shares":14300,"price":18.1,"value":258830.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.70 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4732794,"source":{"system":"sec-edgar","filing":"0001209191-21-014429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121014429/doc4.xml","form_type":"4"}},{"id":2834065,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-25T22:55:26.000Z","date":"2021-02-23","kind":"purchase","acquired":true,"shares":6000,"price":17.04,"value":102240.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.65 to $17.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4718494,"source":{"system":"sec-edgar","filing":"0001209191-21-014429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121014429/doc4.xml","form_type":"4"}},{"id":2837212,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-25T01:27:06.000Z","date":"2021-02-22","kind":"purchase","acquired":true,"shares":9802,"price":18.88,"value":185061.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $18.55 to $19.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").  The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of the Cambrian Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").  The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of the Cambrian Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4712494,"source":{"system":"sec-edgar","filing":"0001209191-21-014048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121014048/doc4.xml","form_type":"4"}},{"id":2841412,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-23T21:15:39.000Z","date":"2021-02-19","kind":"purchase","acquired":true,"shares":11786,"price":19.77,"value":233009.22,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $19.50 to $19.8999, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4702692,"source":{"system":"sec-edgar","filing":"0001209191-21-013165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121013165/doc4.xml","form_type":"4"}},{"id":2847721,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T21:15:55.000Z","date":"2021-02-18","kind":"purchase","acquired":true,"shares":753,"price":19.75,"value":14871.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4690906,"source":{"system":"sec-edgar","filing":"0001209191-21-012342","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121012342/doc4.xml","form_type":"4"}},{"id":2870282,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series BB Preferred Convertible Stock","published_at":"2021-02-10T23:46:28.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":4821996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock,  effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock,  effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock,  effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":100458},"source":{"system":"sec-edgar","filing":"0001209191-21-009413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121009413/doc4.xml","form_type":"4"}},{"id":2870281,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series AA Preferred Convertible Stock","published_at":"2021-02-10T23:46:28.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":110729827,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock,  effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock,  effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock,  effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2306870},"source":{"system":"sec-edgar","filing":"0001209191-21-009413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121009413/doc4.xml","form_type":"4"}},{"id":2870280,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-10T23:46:28.000Z","date":"2021-02-08","kind":"exercise","acquired":true,"shares":2407328,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The total represents shares received upon conversion of shares of Series AA Preferred Stock and Series BB Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock,  effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":4690153,"source":{"system":"sec-edgar","filing":"0001209191-21-009413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121009413/doc4.xml","form_type":"4"}},{"id":2878154,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option  (Right to Buy)","published_at":"2021-02-05T21:41:33.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":16666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36th) of the options granted shall vest and become exercisable each month following February 3, 2021, the Vesting Commencement Date, over three years such that the options shall be 100% vested on the third anniversary of the Vesting Commencement Date, subject to  Continuous Service (as defined in the 2021 Equity Incentive Plan) of James Peyer on the Issuer's Board of Directors, through each such vesting date. Mr. Peyer is the Chief Executive Officer of Cambrian and disclaims beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These options are held by Cambrian Biopharma, Inc., a Delaware corporation (\"Cambrian\"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Dr. Peyer disclaims beneficial ownership of such shares."}],"balance_after":16666,"derivative":{"exercise_price":19,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":16666},"source":{"system":"sec-edgar","filing":"0001209191-21-008092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121008092/doc4.xml","form_type":"4"}}]}